{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:52:43Z","timestamp":1778554363956,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.nano.2022.102646","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T11:43:23Z","timestamp":1671450203000},"page":"102646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Systematic evaluation of the effect of different apolipoprotein A-I mimetic peptides on the performance of synthetic high-density lipoproteins in vitro and in vivo"],"prefix":"10.1016","volume":"48","author":[{"given":"Wenmin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Kuai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily E.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minzhi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis O.","family":"Sviridov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Schwendeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2022.102646_bb0005","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1021\/acsnano.5b07522","article-title":"High-density lipoproteins: nature\u2019s multifunctional nanoparticles","volume":"10","author":"Kuai","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2022.102646_bb0010","first-page":"301","article-title":"A multiple ascending dose study of CSL112, an infused formulation of ApoA-I","volume":"54","author":"Easton","year":"2014","journal-title":"JClinPharmacol"},{"key":"10.1016\/j.nano.2022.102646_bb0015","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1002\/jcb.23188","article-title":"Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice","volume":"112","author":"Vecoli","year":"2011","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.nano.2022.102646_bb0020","series-title":"P. E. J. B. e. B. A.-M. Fielding and C. B. o. Lipids, Cellular cholesterol efflux","first-page":"175","volume":"1533","author":"Fielding","year":"2001"},{"key":"10.1016\/j.nano.2022.102646_bb0025","series-title":"Dynamics of reverse cholesterol transport: protection against atherosclerosis","first-page":"245","volume":"161","author":"Sviridov","year":"2002"},{"key":"10.1016\/j.nano.2022.102646_bb0030","series-title":"Reverse cholesterol transport and cholesterol efflux in atherosclerosis","first-page":"845","volume":"98","author":"Ohashi","year":"2005"},{"key":"10.1016\/j.nano.2022.102646_bb0035","series-title":"Cholesterol efflux and reverse cholesterol transport","first-page":"181","author":"Favari","year":"2015"},{"key":"10.1016\/j.nano.2022.102646_bb0040","series-title":"HDL and reverse cholesterol transport: basic mechanisms and their roles in vascular health and disease","first-page":"1505","volume":"124","author":"Ouimet","year":"2019"},{"key":"10.1016\/j.nano.2022.102646_bb0045","series-title":"Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport","first-page":"1905","volume":"125","author":"Rosenson","year":"2012"},{"key":"10.1016\/j.nano.2022.102646_bb0050","series-title":"Reverse cholesterol transport: molecular mechanisms and the non-medical approach to enhance HDL cholesterol","first-page":"526","volume":"9","author":"Marques","year":"2018"},{"key":"10.1016\/j.nano.2022.102646_bb0055","first-page":"121","volume":"231","author":"Gibson","year":"2021"},{"key":"10.1016\/j.nano.2022.102646_bb0060","series-title":"The CSL112-2001 trial: safety and tolerability of multiple doses of CSL112 (apolipoprotein AI [human]), an intravenous formulation of plasma-derived apolipoprotein AI, among subjects with moderate renal impairment after acute myocardial infarction","first-page":"81","volume":"208","author":"Gibson","year":"2019"},{"key":"10.1016\/j.nano.2022.102646_bb0065","series-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","first-page":"2292","volume":"290","author":"Nissen","year":"2003"},{"key":"10.1016\/j.nano.2022.102646_bb0070","series-title":"Effect of serial infusions of CER-001, a pre-\u03b2 high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial","first-page":"815","volume":"3","author":"Nicholls","year":"2018"},{"key":"10.1016\/j.nano.2022.102646_bb0075","series-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","first-page":"3277","volume":"35","author":"Tardif","year":"2014"},{"key":"10.1016\/j.nano.2022.102646_bb0080","series-title":"Nanobiotechnology, Artificial high-density lipoprotein-mimicking nanotherapeutics for the treatment of cardiovascular diseases","volume":"13","author":"He","year":"2021"},{"key":"10.1016\/j.nano.2022.102646_bb0085","series-title":"Secondary structure changes in ApoA-I Milano (R173C) are not accompanied by a decrease in protein stability or solubility","volume":"9","author":"Petrlova","year":"2014"},{"key":"10.1016\/j.nano.2022.102646_bb0090","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/01.CIR.0000142857.79401.69","article-title":"Differential effects of apolipoprotein AI\u2013mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice","volume":"110","author":"Li","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.nano.2022.102646_bb0095","series-title":"Apolipoprotein and LRP1-based peptides as new therapeutic tools in atherosclerosis","first-page":"3571","volume":"10","author":"Benitez Amaro","year":"2021"},{"key":"10.1016\/j.nano.2022.102646_bb0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2009.07.019","article-title":"Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH2","volume":"208","author":"Datta","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nano.2022.102646_bb0105","first-page":"634","article-title":"5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice","volume":"334","author":"Amar","year":"2010","journal-title":"JPharmacolExpTher"},{"key":"10.1016\/j.nano.2022.102646_bb0110","first-page":"50","article-title":"Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter","volume":"344","author":"Sviridov","year":"2013","journal-title":"JPharmacolExpTher"},{"key":"10.1016\/j.nano.2022.102646_bb0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/ATVBAHA.109.200196","article-title":"The 5A apolipoprotein AI mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro","volume":"30","author":"Tabet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.nano.2022.102646_bb0120","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1194\/jlr.M060285","article-title":"The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties","volume":"56","author":"Schwendeman","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.nano.2022.102646_bb0125","unstructured":"Dasseux et al., 1999J.-L. Dasseux R. Sekul K. Buttner I. Cornut G. Metz J. Dufourcq, 1999. Apolipoprotein AI agonists and their use to treat dyslipidemic disorders, Google Patents"},{"key":"10.1016\/j.nano.2022.102646_bb0130","series-title":"Structural analysis of lecithin: cholesterol acyltransferase bound to high density lipoprotein particles","first-page":"1","volume":"3","author":"Manthei","year":"2020"},{"key":"10.1016\/j.nano.2022.102646_bb0135","series-title":"Activation of lecithin: cholesterol acyltransferase by HDL ApoA-I central helices","first-page":"113","volume":"4","author":"Sorci-Thomas","year":"2009"},{"key":"10.1016\/j.nano.2022.102646_bb0140","series-title":"Role of lecithin: cholesterol acyltransferase in HDL metabolism and atherosclerosis","first-page":"159","author":"Ahsan","year":"2014"},{"key":"10.1016\/j.nano.2022.102646_bb0145","series-title":"Circulation","first-page":"563","article-title":"Single-dose intravenous infusion of ETC-642, a 22-Mer ApoA-I analogue and phospholipids complex, elevates HDL-C in atherosclerosis patients","author":"Khan","year":"2003"},{"key":"10.1016\/j.nano.2022.102646_bb0150","series-title":"Arteriosclerosis Thrombosis and Vascular Biology","article-title":"Single-dose tolerability, pharmacokinetics, and cholesterol mobilization in HDL-C fraction following intravenous administration of ETC-642, a 22-mer ApoA-I analogue and phospholipids complex, in atherosclerosis patients","author":"Miles","year":"2004"},{"key":"10.1016\/j.nano.2022.102646_bb0155","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1194\/jlr.M200157-JLR200","article-title":"Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization","volume":"43","author":"Segall","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.nano.2022.102646_bb0160","first-page":"140","article-title":"Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice","volume":"335","author":"Rousset","year":"2010","journal-title":"JPharmacolExpTher"},{"key":"10.1016\/j.nano.2022.102646_bb0165","series-title":"Western blots lipoproteins and cardiovascular disease","first-page":"369","author":"Freeman","year":"2013"},{"key":"10.1016\/j.nano.2022.102646_bb0170","doi-asserted-by":"crossref","first-page":"D250","DOI":"10.1093\/nar\/gkw712","article-title":"Membranome: a database for proteome-wide analysis of single-pass membrane proteins","volume":"45","author":"Lomize","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nano.2022.102646_bb0175","doi-asserted-by":"crossref","first-page":"D370","DOI":"10.1093\/nar\/gkr703","article-title":"OPM database and PPM web server: resources for positioning of proteins in membranes","volume":"40","author":"Lomize","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.nano.2022.102646_bb0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/MOL.0b013e328338472d","article-title":"High-density lipoprotein heterogeneity and function in reverse cholesterol transport","volume":"21","author":"Rothblat","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.nano.2022.102646_bb0185","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbalip.2011.07.020","article-title":"Influence of C-terminal \u03b1-helix hydrophobicity and aromatic amino acid content on apolipoprotein AI functionality","volume":"1821","author":"Lyssenko","year":"2012","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.nano.2022.102646_bb0190","series-title":"Mimicry of high-density lipoprotein: functional peptide\u2013lipid nanoparticles based on multivalent peptide constructs","first-page":"13414","volume":"135","author":"Zhao","year":"2013"},{"key":"10.1016\/j.nano.2022.102646_bb0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1194\/jlr.M071043","article-title":"Influence of route of administration and lipidation of apolipoprotein AI peptide on pharmacokinetics and cholesterol mobilization","volume":"58","author":"Tang","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.nano.2022.102646_bb0200","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1194\/jlr.M700552-JLR200","article-title":"Apolipoprotein AI mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties","volume":"49","author":"Wool","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.nano.2022.102646_bb0205","series-title":"Phospholipid component defines pharmacokinetic and pharmacodynamic properties of synthetic high-density lipoproteins","first-page":"193","volume":"372","author":"Fawaz","year":"2020"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963422001320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963422001320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:21:18Z","timestamp":1761549678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963422001320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"alternative-id":["S1549963422001320"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2022.102646","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic evaluation of the effect of different apolipoprotein A-I mimetic peptides on the performance of synthetic high-density lipoproteins in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2022.102646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102646"}}